Federal Register / Vol. 62, No. 155 / Tuesday, August 12, 1997 / Notices 43185

activity. The notifications were filed for

the purpose of extending the Act’s

provisions limiting the recovery of

antitrust plaintiffs to actual damages

under specified circumstances.

Specifically, the membership changes

are as follows: Norwest Corporation,

Minneapolis, MN was admitted as a

principal member. Compaq Computer

Corporation, Houston, TX and @Work

Technologies, New York, NY were

admitted as Associate Members.

American Recovery Association, New

Orleans, LA was admitted as an

Advisory Member. The following parties

are no longer members; Equifax Credit

Information Services; Global Concepts,

Inc.; Gemini Computers, Inc.; Raptor

Systems, Inc.; SSDS, Inc.; Home

Financial Network, Inc.; and YCS, Inc.

Membership remains open and the

Consortium intends to file additional

written notifications disclosing all

changes in membership.

The consortium also filed notice that

it has entered into an Agreement for

Strategic Alliance with the Banking

Industry Technology Secretariat

(‘‘BITS’’) as a new activity of the

Consortium.

On October 21, 1993, the Financial

Services Technology Consortium filed

its original notification pursuant to

§ 6(a) of the Act. The Department of

Justice published a notice in the Federal

Register pursuant to § 6(b) of the Act on

December 14, 1993 (58 FR 65399). The

last notification was filed on February 6,

1997. A notice was published in the

Federal Register on March 20, 1997 (62

FR 13394).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 97–21233 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated March 12, 1997, and

published in the Federal Register on

March 19, 1997, (62 FR 13169), Glaxo

Wellcome Inc., Attn: Jeffrey A. Weiss,

1011 North Arendell Avenue, P.O. Box

1217, Zebulon, North Carolina 27597–

2309, made application to the Drug

Enforcement Administration to be

registered as an importer of remifentanil

(9739), a basic class of controlled

substance listed in Schedule II.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Glaxo Wellcome Inc. to

import remifentanil is consistent with

the public interest and with United

States obligations under international

treaties, conventions, or protocols in

effect on May 1, 1971, at this time.

Therefore, pursuant to Section 1008(a)

of the Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations, Section

1301.34, the above firm is granted

registration as an importer of the basic

class of controlled substance listed

above.

Dated: July 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–21247 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Notice of Registration

By Notice dated April 24, 1997, and

published in the Federal Register on

May 12, 1997, (62 FR 25971), Lipomed,

Inc., One Broadway, Cambridge,

Massachusetts 02142, made application

to the Drug Enforcement Administration

to be registered as an importer of the

basic classes of controlled substances

listed below:

Drug Schedule

Cathinone (1235) .......................... I

Methaqualone (2565) ................... I

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ...... I

Mescaline (7381) .......................... I

3,4,5-Trimethoxyamphetamine

(7390).

I

4-Bromo-2, 5-dimethoxyamphetamine (7391).I

4-Methyl-2, 5-dimethoxyamphetamine (7395).I

2,5-Dimethoxyamphetamine

(7396).

I

2,5-Dimethoxy-4-

ethylamphetamine (7399).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Acetyldihydrocodeine (9051) ........ I

Dihydromorphine (9145) ............... I

Heroin (9200) ................................ I

Tilidine (9750) ............................... I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Drug Schedule

Phencyclidine (7471) .................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Methadone (9250) ........................ II

Dextropropoxphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Oxymorphone (9652) .................... II

Alfentanil (9737) ........................... II

Fentanyl (9801) ............................ II

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

section 823(a) and determined that the

registration of Lipomed, Inc. to import

the listed controlled substances is

consistent with the public interest and

with United States obligations under

international treaties, conventions, or

protocols in effect on May 1, 1971, at

this time. Therefore, pursuant to Section

1008(a) of the Controlled Substances

Import and Export Act and in

accordance with Title 21, Code of

Federal Regulations, section 1301.34,

the above firm is granted registration as

an importer of the basic classes of

controlled substances listed above.

Dated: July 28, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–21248 Filed 8–11–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated March 31, 1997, and

published in the Federal Register on

May 8, 1997, (62 FR 25210), Lonza

Riverside, 900 River Road,

Conshohocken, Pennsylvania 19428,

made application by renewal to the

Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Amphetamine (1100) .................... II

Phenylacetone (8501) .................. II

DEA has considered the factors in

Title 21, United States Code, section

823(a), as well as information provided

by other bulk manufacturers, and